Mustbio Overview

  • Year Founded
  • 2021

Year Founded

  • Status
  • Private

  • Employees
  • 17

Employees

  • Latest Deal Type
  • Series C

  • Latest Deal Amount
  • $20.6M

  • Investors
  • 11

Mustbio General Information

Description

Developer of drugs and therapeutics designed to treat cancer. The company offers a biopharmaceutical platform with antibody engineering, multispecific antibody development, immune activation, and preclinical drug development capabilities to create multispecific antibody-based therapies, enabling pharmaceutical companies and oncology researchers to develop targeted immunotherapies for cancer treatment.

Contact Information

Website
www.mustbio.com
Ownership Status
Privately Held (backing)
Financing Status
Venture Capital-Backed
Corporate Office
  • B-701, 102, Edutown-ro
  • Yeongtong-gu, Gyeonggi-do
  • Suwon, Gyeonggi
  • South Korea
+82
Primary Industry
Drug Discovery
Other Industries
Other Pharmaceuticals and Biotechnology
Biotechnology
Vertical(s)
Life Sciences, Oncology
Corporate Office
  • B-701, 102, Edutown-ro
  • Yeongtong-gu, Gyeonggi-do
  • Suwon, Gyeonggi
  • South Korea
+82

Mustbio Timeline

2023202420252026
Financing RoundCaptured Employee CountEstimated Employee Growth

Want detailed data on 11M+ companies?

What you see here scratches the surface

Request a free trial

Want to dig into this profile?

We’ll help you find what you need

Learn more

Mustbio Valuation & Funding

Deal Type Date Amount Raised to Date Post-Val Status Stage
5. Later Stage VC (Series C) 11-Feb-2026 $20.6M Completed Generating Revenue
4. Early Stage VC (Series B) 08-Dec-2022 Completed Pre-Clinical Trials
3. Early Stage VC (Series A) 24-May-2021 Completed Startup
2. Seed Round 01-Mar-2021 $89.8K $89.8K Completed Startup
1. Accelerator/Incubator Completed Startup
To view Mustbio’s complete valuation and funding history, request access »

VC Exit Predictor

See how our proprietary methodology utilizes historical data sets to synthesize the likelihood of an acquisition, IPO, or no exit event. Get a detailed look at the calculations behind our predictions.

Opportunity Score

Calculated using Exit Type probabilities, the company’s stage, and PitchBook’s historical returns data.

Exit Type

Evaluates the likelihood of a successful exit for investors, and the most likely exit type.

Request a free trial

Mustbio Patents

  • 22

    Total Documents Applications and Grants

  • Total Patents Families

  • 9

    Granted

  • 9

    Pending

  • Expiring in next 12 mo

Mustbio Recent Patent Activity

Publication ID Patent Title Status First Filing Date Technology (CPC) Citations
WO-2026121767-A1 Triple fusion protein simultaneously targeting pd-1, vegf, and il-2 receptors Pending 02-Dec-2024
EP-4682170-A1 Novel cd3-binding antibody and multispecific antibody comprising same Pending 13-Mar-2023
US-20260258128-A1 Novel cd3-binding antibody and multispecific antibody comprising same Pending 13-Mar-2023
WO-2024191168-A1 Novel cd3-binding antibody and multispecific antibody comprising same Inactive 13-Mar-2023
JP-2025527694-A Il2 mutant and protein complex containing same Active 23-Aug-2022 C07K14/55
To view Mustbio’s complete patent history, request access »

Mustbio Signals

Growth Rate

Weekly
Growth
Weekly Growth

Size Multiple

Median
Size Multiple

Key Data Points

Similarweb Unique Visitors

Majestic Referring Domains

PitchBook’s non-financial metrics help you gauge a company’s traction and growth using web presence and social reach.

Request a free trial

Mustbio Investors (11)

Investor Name Investor Type Holding Investor Since Participating Rounds
Atinum Investment Venture Capital Minority
BNH Investment Venture Capital Minority
Shinhan Capital Venture Capital Minority
GeneN Investment Partners Venture Capital Minority
Korea Development Bank VC-Backed Company Minority
You’re viewing 5 of 11 investors. Get the full list »

Ready to get started?

Request a free trial

Mustbio FAQs

  • When was Mustbio founded?

    Mustbio was founded in 2021.

  • Where is Mustbio headquartered?

    Mustbio is headquartered in Suwon, South Korea.

  • What is the size of Mustbio?

    Mustbio has 17 total employees.

  • What industry is Mustbio in?

    Mustbio’s primary industry is Drug Discovery.

  • Is Mustbio a private or public company?

    Mustbio is a Private company.

  • What is Mustbio’s current revenue?

    The current revenue for Mustbio is .

  • How much funding has Mustbio raised over time?

    Mustbio has raised $41M.

  • Who are Mustbio’s investors?

    Atinum Investment, BNH Investment, Shinhan Capital, GeneN Investment Partners, and Korea Development Bank are 5 of 11 investors who have invested in Mustbio.

Data Transparency

  • Meet our data hygiene team

    Discover how our experts ensure you’re getting the most accurate financial data in the industry.

    Read more

  • How PitchBook sources data

    Our data operations team has logged over 3.5 million hours researching, organizing, and integrating the information you need most.

    Discover our process